Introduction Recombinant human growth hormone (r-hGH) for growth hormone deficiency (GHD) has been available free in the state hospitals of Sri Lanka since 2009.
Introduction
Recombinant human GH (r-hGH) has been used in the treatment of children with growth hormone deficiency (GHD) since 1985 with a good safety profile [1, 2, 3] . Safety surveillance programme which included more than 60,000 children from 50 countries concluded that r-hGH was a safe and effective replacement therapy [4] .
Most of those diagnosed with GHD in Sri Lanka did not receive GH treatment until 2009 when it was made available free in state hospitals. This is the first report Vol. 60 
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Papers from Sri Lanka based on the data from one unit at the Lady Ridgeway Hospital, Colombo, on the auxological outcome of therapy in a cohort of GH deficient patients treated with r-hGH. The objectives of the study were to compare height standard deviation scores (SDS) before and after treatment and heights at final assessment in relation to the target height (TH) and target height range based on their parents' heights.
Methods
The study group consisted of GH deficient patients followed up in the University Paediatric Unit at the Lady Ridgeway Hospital, Colombo since 2005 who had completed GH therapy. They were initially referred for assessment of short stature which was confirmed according to the definition of the height being more than two standard deviations below the population mean or below the 3rd percentile for age and sex [3, 5] . They were examined at presentation and the relevant investigations were performed to exclude the presence of a chronic illness, skeletal and genetic disorders and other endocrine causes resulting in short stature [3] . Following the preliminary screening investigations including skeletal age, GHD was confirmed by a single provocation test using glucagon [3, 6] . GHD was diagnosed when the peak stimulated GH using the ELISA technique, was less than 3.8 ng/ml (<10 mU/l)and partial deficiency was defined as a peak stimulated level of 3.8 to 7.6 ng/ml (10-20 mU/l) [6, 7, 8] . All had imaging of the hypothalamic-pituitary region prior to therapy [3] . They were treated with r-hGH at an initial dose of 4.5 mg/m 2 / week [8, 9] given by daily subcutaneous injections in the evening to simulate the normal physiology [10, 11] . Dose adjustments were made periodically when indicated.
They were prospectively followed up and routine examinations and regular anthropometric measurements were carried out by one investigator and biochemical and radiological investigations were performed when indicated until cessation of therapy. The heights were measured using a wall mounted stadiometer. Treatment was discontinued at a predetermined skeletal age or when puberty was established or at the patient's and or parents' request [8] .
The patients' pre and post treatment height standard deviation scores (SDS) were calculated using the LMS growth programme version 2.69 (2010) using WHO Child and 5-19 growth reference standards (2006/2007) . The significance of these findings was determined using the paired t test.
The target height (TH) or mid-parental height for each patient was calculated based on their parents' heights and the TH range was arrived at using the following formulae [12] . Target height for girls = Mother's height + father's height -13 cm ÷2. Target height for boys = Mother's height + father's height + 13 cm ÷2. Target height range = TH + 8.5 cm.
The heights of the patients at final assessment were compared with the TH and TH range thus calculated to determine the auxological outcome of therapy.
Ethics clearence was obtained from the Ethics Review Committee of the Faculty of Medicine, Colombo. Written informed consent was obtained from parents.
Results
Sixteen patients (15 boys Of the 16 patients, 9 were deficient in GH on provocative testing while others showed a partial deficiency. One patient each had deficiency of TSH and ACTH initially and subsequently during follow up, six developed deficiency of TSH, and one also had associated ACTH deficiency. The gonadotrophin levels prior to treatment were not assessed as the appropriate stimulation test could not be performed. Subsequently all the boys went into puberty naturally whereas the girls needed hormone replacement therapy. Hypoplasia of the pituitary gland was seen in eight patients on neuro-imaging while the posterior pituitary gland was not affected in any of them.
Treatment with r-hGH resulted in a significant increase in the height SDS at cessation of therapy: -4.438 (1.18) to -3.37 (0.81), p<0.001 (Table 1) . The height velocity during the first year of therapy ranged from 5 cm to 12.2 cm, mean 7.99 (SD = 2.12) and the increment in height observed was 7.2 cm to 43.5 cm with 10 patients gaining 25 cm at the end of treatment (Table 1) . Their ages at final assessment ranged from 15 years 10 months to 26 years 9 months, mean 232 (SD + 32.37) months. Although only one patient had reached the TH, six were within the TH range ( Table 2) . None of the patients experienced any complications of therapy.
Discussion
GH was first isolated from human cadaveric pituitary glands in 1956 and the pituitary derived GH was used for the first time on a child with GHD by Maury Raben in 1958 [10, 11, 13, 14] . Use of this preparation was suspended in 1985 due to concerns about the association with Creutzfeldt-Jakob disease with pituitary derived GH [2, 11] . Identification of the biochemical structure of GH in 1972 and progress in molecular biology prompted the process of manufacturing a recombinant human GH preparation in 1981 and in 1985 this product was approved for use in GHD [10, 11] . Since then r-hGH has been used for several conditions other than GHD [1, 10, 11] . GH is not essential for life but it is essential for linear growth. If deficient and not treated the very short child will grow up to be an extremely short adult (125 to 130 cm) as GH accounts for approximately 38 cm of post natal growth in boys and 33 cm in girls [15] .
Presence of GHD in Sri Lankan children was first documented in 1991 [16] . Following a meticulous screening and diagnostic process and based on TannerWhitehouse standards a prevalence of 1:1300 for GHD was reported [5, 16] . A more recent publication describes the outcome of r-hGH treatment after a mean duration of 17.6 months in 21 adolescents with conditions including GHD, Turner syndrome and Prader-Willi syndrome [17] .We reported the psychological status of children with GHD and their parents in 2011 [18] . Forty children with GHD (including 13 in the present study) were assessed using the Perso-nality Assessment Questionnaire (PAQ) administered prior to treatment. Psychological maladjustment was observed in 24 (60%) and 54% of the parents were similarly affected as measured by the General Health Questionnaire-30 (GHQ-30).
To obtain the best auxological outcome of GH therapy, treatment should be started as early as possible, as younger the age of starting treatment, better the outcome [3, 9] . Most children would reach their genetic potential with GH therapy, but the response is variable and some patients fail to achieve their potential especially when treatment is started at an older age [2, 19] . In our cohort, treatment resulted in only seven patients (43.8%) reaching the TH/TH range. Our patients presented late as they were diagnosed at a mean age of 145.38 months and treatment was started at a mean age of 164.75 months due to financial constraints. The increment may have been greater if they had presented earlier and were treated at a younger age.
Six of our patients purchased GH initially but due to the expense it was not given regularly. The monthly income of these families ranged from Rs 10,000.00 to 60,000.00 with only two families earning Rs 50,000.00 a month. Therefore it was not affordable for most of the parents until it was available free in 2009. Optimal treatment during the first two years of therapy is crucial to achieve the best outcome [19] . But the supply of GH was not always continuous and therefore the treatment was intermittent at times which may have contributed to the final outcome in our patients.
Although not formerly assessed, all of them were happy with the outcome of therapy and the psychological benefit appeared to be immense. More patients in our cohort could have reached the TH/TH range thus improving their auxological outcome if they could have commenced treatment at a younger age and the availability of GH was continuous. We did not reassess the secretory status of GH after stopping treatment to identify those likely to benefit from continuing GH therapy as adults [1, 3, 9] . Once treatment was completed they were referred to adult endocrine services for follow up.
Introduction
Infertility is known to affect around one in six couples worldwide [1] . In some no abnormality can be found, therefore termed as having unexplained infertility. The prevalence of male factor infertility is thought to be around 20-40% while unexplained infertility is estimated to be around 10-28% [2] [3] [4] [5] . Augmentation of ovulation is widely used to improve fertility in women with unexplained infertility and also as an adjunct to intrauterine insemi-nation in male factor infertility. Clomifene citrate (CC) is the commonest anti-oestrogen used for induction and augmentation of ovulation. A third generation aromatase inhibitor letrozole is a newer therapeutic agent proposed for same purposes. It is proposed that letrozole has some advantages over CC
